Access to Medicine Foundation

Name

Access to Medicine Foundation

Legal name

Access to Medicine Foundation

Website

https://accesstomedicinefoundation.org

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Healthcare Research and Pharmaceutical Benchmarking

SIC

Services-Health Services (8000)

akta.pro primary industry

Access Policy, Advocacy & Stakeholder Management (HLAIAKAL)

akta.pro secondary industries

Value Dossier & Evidence Generation (AMCP/Global Value Dossier) (HLAIAKAC), Health & Medical Research Grantmaking Foundations (BPAGAKAL), Health Supply Chain, Procurement & Access to Medicines (BPADAIAI)

Keywords

• Pharmaceutical benchmarking research
• Access to medicine
• Antimicrobial resistance assessment
• Health equity research
• Generics access programs

Headquarters

HQ city

Amsterdam

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Distribution channels1 record

Marketing channels12 records

Core offering

The Access to Medicine Foundation produces evidence-based research and independent benchmarking of pharmaceutical company performance on access to medicine in low- and middle-income countries. Its core offerings are the Access to Medicine Index, the AMR Benchmark, the Access to Generics programme, and the Diabetes Care Programme, supported by company-specific report cards and stakeholder convenings that engage the pharmaceutical industry, investors, governments, and global health organisations.

Product overview

The Access to Medicine Foundation is an independent non-profit organization that operates as a research and convening organization rather than a traditional product company. Its core offerings consist of evidence-based benchmarking programmes: the Access to Medicine Index (ranking 20 major pharmaceutical companies), the AMR Benchmark (assessing 25 companies on antimicrobial resistance), and the Access to Generics programme (evaluating generic medicine manufacturers). These are supported by thematic programmes on Diabetes Care and Antimicrobial Resistance, a Research Hub for publications and findings, individual Company Report Cards, and engagement initiatives like the Amsterdam Sessions and the Investor Action on AMR initiative. The Foundation also produces content through The Health Equity Podcast and Health Equity through Her Lens initiative. All offerings focus on stimulating and guiding healthcare companies to improve access to essential medicines in low- and middle-income countries.

Differentiator

Problem solved

Functional benefit

Brands

• Access to Medicine Index: Investor-relevant, transparent measure of pharmaceutical company behaviour on access to medicine
• AMR Benchmark
• Diabetes Care Programme

Products and services

• Access to Medicine Index An investor-relevant, transparent ranking of 20 of the world's largest research-based pharmaceutical companies on their efforts to improve access to medicines, vaccines, and diagnostics in low- and middle-income countries.
• AMR Benchmark The longest-running independent assessment of the pharmaceutical industry's response to drug-resistant infections, evaluating companies on R&D, Responsible Manufacturing, and Appropriate Access & Stewardship.
• Access to Generics programme Assessment programme evaluating generic medicine manufacturers on their efforts to expand access to essential off-patent medicines in low- and middle-income countries.
• Diabetes Care Programme A dedicated programme launched in 2022 to drive improvements in access to diabetes care worldwide, assessing industry practice and engaging key players to expand access to insulin and diabetes management products in LMICs.
• Antimicrobial Resistance Programme Research programme working since 2017 to move pharmaceutical companies to combat drug-resistant infections through evidence-based assessments and stakeholder engagement.
• Research Hub A centralized platform providing access to evidence-based research findings, company profiles, report cards, and other changemaking tools from the Foundation's work.
• Company Report Cards Individual company assessments evaluating the actions pharmaceutical companies are taking to address key access-to-medicine priorities and highlighting areas for improvement.

Quantifiable outcome

• Companies with board-level accountability grew from 11 to 17 between 2018 and 2024
• +4 more outcomes

Named customers8 records

Segments7 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

13 partnerships are on record, tiered core and minor.

• World Health Organization (WHO)coreStrategic or Co-development Partner · 22 November 2023Collaboration during World AMR Awareness Week 2023, including a joint webinar on responsible manufacturing. The Foundation participates in the open consultation process for the updated Global Action Plan (GAP) on AMR following UNGA.
• Global Antibiotic Research and Development Partnership (GARDP)coreStrategic or Co-development Partner · 28 June 2022Organized expert panel discussion in The Hague on integrating Dutch, European and global efforts on AMR R&D and appropriate access to antibiotics. GARDP's Jennifer Cohn discussed the value of partnerships in advancing R&D and improving access to new antibiotics in LMICs.
• Accord for a Healthier World (Pfizer)coreStrategic or Co-development Partner · 1 May 2022Pfizer launched 'An Accord for a Healthier World' providing its patented, high-quality medicines and vaccines on a not-for-profit basis in 45 lower-income countries. The Foundation's 2021 Index recommendations directly influenced this initiative.
• Sanofi Global Health UnitcoreStrategic or Co-development Partner · 1 September 2021Sanofi launched its Global Health Unit (GHU) in September 2021, aiming to increase access to 30 products across 40 countries with a focus on non-communicable diseases. The 2021 Access to Medicine Index directly influenced this company's decision to create the GHU.
• Investor Action on Antimicrobial Resistance initiativecoreStrategic or Co-development Partner · 1 January 2020Launched in 2020, this initiative focuses on the role of capital markets in tackling the global threat of rising drug-resistant infections. The Foundation works with investors directly, helping them engage pharma companies through roundtable discussions, research launches, collective calls to action and collaborative engagements.
• Clinton Health Access Initiative (CHAI)coreStrategic or Co-development PartnerViatris is a member of the Cancer Access Partnership (CAP), established by CHAI and the American Cancer Society, aiming to increase affordability and availability of 26 key cancer treatments in selected LMICs.
• Stop TB PartnershipcoreStrategic or Co-development PartnerThrough the Stop TB Partnership's Global Drug Facility, companies like Viatris supply products to countries with high burden of MDR-TB, including over 36 countries in the last three years.
• Medicines Patent Pool (MPP)coreStrategic or Co-development PartnerViatris is a sublicensee of voluntary licensing agreements facilitated by MPP, including for dolutegravir (paediatric) for HIV and cabotegravir long-acting for PrEP.
• Drugs for Neglected Disease initiative (DNDi)coreStrategic or Co-development PartnerPartnership with DNDi to develop a sustained-release formulation of flucytosine for paediatric patients with advanced HIV, aiming to ease self-administration and improve patient adherence.
• TB AlliancecoreStrategic or Co-development PartnerViatris was granted a non-exclusive voluntary licensing agreement by TB Alliance for pretomanid, a multi-drug-resistant TB medicine, to commercialize in LMICs. Partnership includes price reduction through volume guarantee with MedAccess.
• Chatham House Centre for Universal HealthminorStrategic or Co-development PartnerRobert Yates, Executive Director, interviewed about the Foundation's impact on global health policy.
• Africa Public Health FoundationminorStrategic or Co-development PartnerDr. Ebere Okereke, CEO, interviewed about how the Foundation's reports help identify priorities and challenges for manufacturers.
• Desmond Tutu Health FoundationminorStrategic or Co-development PartnerDr. Linda-Gail Bekker, CEO, interviewed on how the Foundation helps create environment for companies to increase access.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Drugs for Neglected Diseases initiative (DNDi): Independent non-profit R&D organization developing treatments for neglected diseases in LMICs. Direct peer: both are non-profit organizations focused on improving pharmaceutical access and outcomes in low- and middle-income countries, with overlapping partner networks (DNDi is itself a Foundation partner).
• Medicines Patent Pool (MPP): UN-backed public health organization that facilitates voluntary licensing of essential medicines to enable affordable access in LMICs. Direct peer: operates in the same pharmaceutical access-for-LMICs space with overlapping partners and an evidence-based, multi-stakeholder engagement model.

Peers

• Clinton Health Access Initiative (CHAI):

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/atmindex

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Access to Medicine Foundation